Polymorphisms in TS, MTHFR and ERCC1 genes as predictive markers in first-line platinum and pemetrexed therapy in NSCLC patients

Journal of Cancer Research and Clinical Oncology

Volumn 140, Issue 12, 2014, Pages 2047-2057

  Krawczyk, Paweł ^a   Kucharczyk, Tomasz ^a,b   Kowalski, Dariusz M ^c   Powrózek, Tomasz ^a   Ramlau, Rodryg ^d,e   Kalinka Warzocha, Ewa ^f   Winiarczyk, Kinga ^c   Knetki Wróblewska, Magdalena ^c   Wojas Krawczyk, Kamila ^a   Kałakucka, Katarzyna ^a   Dyszkiewicz, Wojciech ^d,e   Krzakowski, Maciej ^c   Milanowski, Janusz ^a,g  

^a MEDICAL UNIVERSITY OF LUBLIN   (Poland)

^b MEDICAL UNIVERSITY OF WARSAW   (Poland)

^c INSTITUTE OF ONCOLOGY   (Poland)

^d Wielkopolska Center of Pulmonology and Thoracosurgery of Eugenia and Janusz Zeyland   (Poland)

^e POZNAN UNIVERSITY OF MEDICAL SCIENCES   (Poland)

^f Regional Oncological Centre   (Poland)

^g INSTITUTE OF AGRICULTURAL MEDICINE   (Poland)

Author keywords

Gene polymorphisms; Non small cell lung cancer; Pemetrexed; Platinum compounds

Indexed keywords

ANTINEOPLASTIC AGENT; DNA BINDING PROTEIN; ENDONUCLEASE; ERCC1 PROTEIN, HUMAN; GLUTAMIC ACID DERIVATIVE; GUANINE; METHYLENETETRAHYDROFOLATE REDUCTASE (NADPH2); MTHFR PROTEIN, HUMAN; PEMETREXED; PLATINUM; THYMIDYLATE SYNTHASE; TUMOR MARKER;

AGED; ANALOGS AND DERIVATIVES; CARCINOMA, NON-SMALL-CELL LUNG; CLINICAL TRIAL; FEMALE; GENETICS; HUMAN; LUNG NEOPLASMS; MALE; MIDDLE AGED; MORTALITY; MULTICENTER STUDY; PROPORTIONAL HAZARDS MODEL; RETROSPECTIVE STUDY; SINGLE NUCLEOTIDE POLYMORPHISM;

AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, NON-SMALL-CELL LUNG; DNA-BINDING PROTEINS; ENDONUCLEASES; FEMALE; GLUTAMATES; GUANINE; HUMANS; LUNG NEOPLASMS; MALE; METHYLENETETRAHYDROFOLATE REDUCTASE (NADPH2); MIDDLE AGED; PLATINUM; POLYMORPHISM, SINGLE NUCLEOTIDE; PROPORTIONAL HAZARDS MODELS; RETROSPECTIVE STUDIES; THYMIDYLATE SYNTHASE; TUMOR MARKERS, BIOLOGICAL;

EID: 84925231299     PISSN: 01715216     EISSN: 14321335     Source Type: Journal    
DOI: 10.1007/s00432-014-1756-6     Document Type: Article

References (32)

1. Al-Saleh K, Quinton C, Ellis PM (2012) Role of pemetrexed in advanced non-small-cell lung cancer: meta-analysis of randomized controlled trials, with histology subgroup analysis. Curr Oncol 19(1):e9–e15
2. Arévalo E, Castañón E, López I et al (2014) Thymidylate synthase polymorphisms in genomic DNA as clinical outcome predictors in a European population of advanced non-small cell lung cancer patients receiving pemetrexed. J Transl Med 12(1):98
3. Bukhari AA, Goudar RK (2013) Thymidylate synthase as predictive biomarker for pemetrexed response in NSCLC. Lung Cancer Inter 436409:1–7
4. Ceppi P, Volante M, Saviozzi S et al (2006) Squamous cell carcinoma of the lung compared with other histotypes shows higher messenger RNA and protein levels for thymidylate synthase. Cancer 107(7):1589–1596
5. Chattopadhyay S, Moran RG, Goldman D (2007) Pemetrexed: biochemical and cellular pharmacology. Mol Cancer Ther 6(2):404–417
6. Dela Cruz CS, Tanoue LT, Matthay RA (2011) Lung cancer: epidemiology, etiology, and prevention. Clin Chest Med 32:605–644
7. Dotor E, Cuatrecases M, Martínez-Iniesta M et al (2006) Tumor thymidylate synthase 1494del6 genotype as a prognostic factor in colorectal cancer patients receiving fluorouracil-based adjuvant treatment. J Clin Oncol 24(10):1603–1611
8. Friboulet L, Olaussen KA, Pignon JP et al (2013) ERCC1 isoform expression and DNA repair in non-small-cell lung cancer. N Engl J Med 368:1101–1110
9. Frosst P, Blom HJ, Milos R et al (1995) A candidate genetic risk factor for vascular disease: a common mutation in methylenetetrahydrofolate reductase. Nat Genet 10(1):111–113
10. Gazdar AF (2007) DNA repair and survival in lung cancer—the two faces of Janus. N Engl J Med 356(8):771–773
11. Hanauske AR, Eismann U, Oberschmidt O et al (2007) In vitro chemosensitivity of freshly explanted tumor cells to pemetrexed is correlated with target gene expression. Invest New Drugs 25:417–423
12. Hu Q, Li X, Su C et al (2012) Correlation between thymidylate synthase gene polymorphisms and efficacy of pemetrexed in advanced non-small cell lung cancer. Exp Ther Med 4(6):1010–1016
13. Iacopetta B, Grieu F, Joseph D, Elsaleh H (2001) A polymorphism in the enhancer region of the thymidylate synthase promoter influences the survival of colorectal cancer patients treated with 5-fluorouracil. Br J Cancer 85(6):827–830
14. Kawakami K, Watanabe G (2003) Identification and functional analysis of single nucleotide polymorphism in the tandem repeat sequence of thymidylate synthase gene. Cancer Res 63:6004–6007
15. Kumar K, Vamsy M, Jamil K (2010) Thymidylate synthase gene polymorphisms effecting 5-FU response in breast cancer patients. Cancer Biomark 6(2):83–93
16. Lee SH, Noh KB, Lee JS et al (2013) Thymidylate synthase and ERCC1 as predictive markers in patients with pulmonary adenocarcinoma treated with pemetrexed and cisplatin. Lung Cancer 81(1):102–108
17. Li WJ, Jiang H, Fang XJ et al (2013) Polymorphisms in thymidylate syntase and reduced folate carrier (SLC19A1) genes predict survival outcome in advanced non-small cell lung cancer patients treated with pemetrexed-based chemotherapy. Oncol Lett 5(4):1165–1170
18. Mandola MV, Stoehlmacher J, Muller-Weeks S et al (2003) A novel single nucleotide polymorphism within the 5′ tandem repeat polymorphism of the thymidylate synthase gene abolishes USF-1 binding and alters transcriptional activity. Cancer Res 63(11):2898–2904
19. Mandola MV, Stoehlmacher J, Zhang W et al (2004) A 6 bp poly-morphism in the thymidylate synthase gene causes message instability and is associated with decreased intratumoral TS mRNA levels. Pharmacogenetics 14:319–327
20. Mlak R, Krawczyk P, Ramlau R et al (2013) Predictive value of ERCC1 and RRM1 gene single-nucleotide polymorphisms for first-line platinum- and gemcitabine-based chemotherapy in non-small cell lung cancer patients. Oncol Rep 30(5):2385–2398
21. Scagliotti GV, Parikh P, von Pawel J et al (2008) Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer. J Clin Oncol 26:3543–3551
22. Scagliotti G, Hanna N, Fossella F et al (2009) The differential efficacy of pemetrexed according to NSCLC histology: a review of two phase III studies. Oncologist 14(3):253–263
23. Scagliotti G, Brodowicz T, Shepherd FA et al (2011) Treatment-by-histology interaction analyses in three phase III trials show superiority of pemetrexed in nonsquamous non-small cell lung cancer. J Thorac Oncol 6:64–70
24. Sculier JP, Moro-Sibilot D (2009) First- and second-line therapy for advanced non-small cell lung cancer. Eur Respir J 33:915–930
25. Smit EF, Burgers SA, Biesma B et al (2009) Randomized phase II and pharmacogenetic study of pemetrexed compared with pemetrexed plus carboplatin in pretreated patients with advanced non–small-cell lung cancer. J Clin Oncol 27(12):2038–2045
26. Sohn KJ, Croxford R, Yates Z, Lucock M, Kim YI (2013) Effect of the methylenetetrahydrofolate reductase C677T polymorphism on chemosensitivity of colon and breast cancer cells to 5-fluorouracil and methotrexate. J Natl Cancer Inst 96(2):134–144
27. Stoehlmacher J, Goekkurt E, Hoeffken G et al (2009) Thymidylate synthase polymorphisms and immunohistochemistry in non-small cell lung cancer. J Clin Oncol 27(suppl):11101
28. Tiseo M, Giovannetti E, Tibaldi C et al (2012) Pharmacogenetic study of patients with advanced non-small cell lung cancer (NSCLC) treated with second-line pemetrexed or pemetrexed-carboplatin. Lung Cancer 78(1):92–99
29. Uchida K, Hayashi K, Kawakami K et al (2004) Loss of heterozygosity at the thymidylate synthase (TS) licus on chromosome 18 affects tumor response and survival in individuals heterozygous for a 28-bp polymorphism in the TS gene. Clin Cancer Res 10:433–439
30. Wang X, Wang Y, Wang Y, Cheng J, Wang Y, Ha M (2013) Association of thymidylate synthase gene 3′-untranslated region polymorphism with sensitivity of non-small cell lung cancer to pemetrexed treatment: TS gene polymorphism and pemetrexed sensitivity in NSCLC. J Biomed Sci 25(20):5
31. Wang L, Wang R, Pan Y, Sun Y, Zhang J, Chen H (2014) The pemetrexed-containing treatments in the non-small cell lung cancer, is −/low thymidylate synthase expression better than +/high thymidylate synthase expression: a meta-analysis. BMC Cancer 19(14):205
32. Zheng Z, Chen T, Li X, Haura E, Sharma A, Bepler G (2007) DNA synthesis and repair genes RRM1 and ERCC1 in lung cancer. N Engl J Med 356(8):800–808